Search
Anthoxanthum odoratum
go.drugbank.com/drugs/DB14163ApprovedAnthoxanthum odoratum allergenic extract is used in allergenic testing.
Categories: Non-Standardized Food Allergenic ExtractICA-105665
go.drugbank.com/drugs/DB06089InvestigationalIt is a novel opener of the KCNQ ion channel which in preclinical studies has demonstrated a broad spectrum of activity in models of epilepsy. … In addition, ICA-105665 has also demonstrated activity in certain models of neuropathic pain.
Carboprost tromethamine
go.drugbank.com/drugs/DB00429ApprovedInvestigationalA nonsteroidal abortifacient agent that is effective in both the first and second trimesters of pregnancy.
Dichlorvos
go.drugbank.com/drugs/DB11397ExperimentalVet approvedThe compound has been available on the market since 1961 and its use is a controversial topic due to environmental and health concerns. … Dichlorvos is found in urban waterways and its toxicity may impact humans, leading to poisoning, neurotoxicity, and cancer.
Categories: Compounds used in a research, industrial, or household settingZD4407
go.drugbank.com/drugs/DB06539ExperimentalIt entered Phase 1 clinical trials for chronic obstructive pulmonary disease (COPD) in the United Kingdom but was discontinued during this phase in March 2003 … The drug ZD4407, an antiasthmatic developed by AstraZeneca, functions as a 5-lipoxygenase inhibitor.
Brigatinib
go.drugbank.com/drugs/DB12267ApprovedInvestigational[A31313] Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.[L1026] … [A31311] It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma.
Navepegritide
go.drugbank.com/drugs/DB17824ApprovedInvestigationalallows for once-weekly dosing while providing sustained systemic exposure to CNP, which antagonizes the overactive fibroblast growth factor receptor 3 (FGFR3) signaling pathway responsible for impaired bone … growth in individuals with achondroplasia.
Udenafil
go.drugbank.com/drugs/DB06267ApprovedUdenafil is a new phosphodiesterase type 5 (PDE5) inhibitor used to treat erectile dysfunction (ED). It has been approved in South Korea and will be marketed under the brand name Zydena. … It is not yet approved for use in the U.S., E.U., or Canada.
Categories: Drugs Used in Erectile DysfunctionWarfarin
go.drugbank.com/drugs/DB00682ApprovedInvestigationalAlthough originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. … Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration.
Categories: Compounds used in a research, industrial, or household settingPegaptanib
go.drugbank.com/drugs/DB04895ApprovedWithdrawnPegatinib aids neovascular age-related macular degeneration by binding to VEGF which in order reduces angiogenesis and vessel permeability. Pegaptanib was granted FDA approval on 17 September 2004.